[Effect of CYP2C19 gene polymorphism on eradication treatment efficacy of Helicobacter pylori infection].
Kucheriavyĭ
Iu A
IuA
D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D001944:Breath Tests; D017291:Clarithromycin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D015331:Cohort Studies; D065731:Cytochrome P-450 CYP2C19; D004247:DNA / Q000235:genetics; D004359:Drug Therapy, Combination; D016145:Endoscopy, Digestive System; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000201:enzymology / Q000453:epidemiology / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D009031:Moscow / Q000453:epidemiology; D009853:Omeprazole / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000201:enzymology / Q000453:epidemiology / Q000382:microbiology; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies
D000658:Amoxicillin; D004247:DNA; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D017291:Clarithromycin; D009853:Omeprazole